# Dapagliflozin in STEMI

Study · id `cardio:ct-nct06174753` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06174753](<https://clinicaltrials.gov/study/NCT06174753>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06174753

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 256 participants.

## Technical summary

Registry record NCT06174753. Randomized; triple masking; primary purpose treatment. Start 2025-01-20 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 256 participants (planned count; ClinicalTrials.gov record NCT06174753, source copy `cardio:ctgov-nct06174753-2026-02-20`, retrieved 2026-10-26)
- Started: 2025-01-20 (actual) (ClinicalTrials.gov record NCT06174753, source copy `cardio:ctgov-nct06174753-2026-02-20`, retrieved 2026-10-26)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT06174753, source copy `cardio:ctgov-nct06174753-2026-02-20`, retrieved 2026-10-26)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06174753, source copy `cardio:ctgov-nct06174753-2026-02-20`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT06174753, source copy `cardio:ctgov-nct06174753-2026-02-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06174753-2026-02-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin in STEMI
- Acronym: DAPA STEMI
- Condition: ST Elevation Myocardial Infarction
- Condition: Myocardial Infarction
- Intervention (Drug): Dapagliflozin 10mg Tab
- Intervention (Diagnostic test): CMR
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)

## Provenance

Content hash: 3f55ab840424d681a395fd272fa1d5d13619804c4386729685c0243a71a3bd7c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
